The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.Xoma Royalty, which has recently built a business out of acquiring struggling biotechnology companies, has secured its latest target.In announcement late Monday, Xoma said […]
